| Customization: | Available |
|---|---|
| CAS No.: | 1208243-50-8 |
| Formula: | C51h84n16o21 |
|
Still deciding? Get samples of US$ 90/box
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
"Clearance of damaged tissue can facilitate renal repair and promote immune tolerance. Therefore, the augmentation of phagocytosis of macrophages is likely to be one of the mechanisms for the renoprotective effect of EPO as well. Such hypothesis does not contradict with our study, in which we focused the functional switch of macrophages."
"Commonly defined by in vitro experiments, macrophage activation can be distinguished for two major subtypes: classically activated M1 macrophages are pro-inflammatory and exert deleterious effect in sterile tissue injuries; in contrast, alternatively activated M2 macrophages are characterized by immunoregulatory and tissue repair capabilities. Although indeed simplistic, this essential classification is well accepted and explains the functional plasticity and dynamics of macrophages in response to different insults in vivo. Typically, renal macrophages are a heterogeneous group with their phenotypes changing under physiological and pathological conditions."
"Erythropoietin protects against rhabdomyolysis-induced acute kidney injury by modulating macrophage polarization."
"EPO inhibited pro-inflammatory response in M1 macrophages. ... have also been confirmed in nonerythropoietic EPO derivative ARA290."
"EPO could only inhibit apoptosis, but not necroptosis that are more destructive and pro-inflammatory. On the other hand, EPO decreases the level of secreted chemokine CCL7, thus consequently suppresses the migration of monocytes into kidneys. Moreover, EPO can directly inhibit the activation of M1 subtypes and promotes polarization toward M2 phenotypes. As a result, the M1/M2 ratio during rhabdomyolysis-induced acute kidney injury is favorably regulated toward an anti-inflammatory phenotype and thereby ameliorates the renal damages"
| Items | Specifications |
| Business Type | We are a manufacturer of GMP peptide and provide OEM service. The lid also can be customized |
| Filling amount | The filling amount is 2-5mg extra per bottle. |
| Purity | The purity is above 99% |
| Price | Competitive price |
| Delivery time | The delivery time is stable and short. If you pay before 12 a.m,the goods can be shipped on the same day. |
| Shipping risk | If the package was lost we will resend the goods to you,so you won't suffer a loss if you buy it. |
Zhaobo Bio acquired early mastery of development and manufacturing of peptides, the short chain amino acids linked by peptide bonds that have enabled new generations of small molecule drugs that closely mimic the body's natural pathways.
Now Zhaobo Bio possesses first-class capabilities to manufacture peptides at industrial scale and in full compliance with the strictest Good Manufacturing Practice (GMP) standards.
Upstream peptide synthesis
Zhaobo Bio production plants are endowed with state-of-the-art equipment for solvent supply, peptide synthesis, purification and isolation of active ingredients and intermediates. All equipment and containment is GMP qualified and cleaning validated. Overlapping capacities and sizes of different equipment trains facilitate a smooth scale-up for increases in demand within the product life cycle.
Downstream purification and isolation of peptides
Zhaobo Bio is committed to the systematic expansion and modernization of its purification equipment in order to ensure the efficient production of ever-increasing amounts of bulk peptide pharmaceuticals.
It uses sophisticated methods for large scale purification campaigns such as preparative high performance liquid chromatography (HPLC), ion exchange (IEX), size-exclusion chromatography (SEC), and ultra-filtration (UF/TFF). The equipment in place permits highly efficient or even continuous manufacturing of extremely pure products up to multi-kg quantities per lot.
For preparative HPLC, dynamic axial compression (DAC) stainless steel columns of up to 60 cm diameter both in batch and continuous mode are packed with the appropriate high performance silica separation phase. For low-pressure chromatography columns up to 80 cm diameter are available. Solvent delivery is ensured from eluent tank farms and containers.
The control of microbiological contamination is a prerequisite for API manufacturing. Class D (ISO 8) and C (ISO 7) clean rooms are supplied via HEPA-filtered, temperature and humidity controlled air, down-flow booths are used for minimizing microbial contamination and protecting operators. Highly active pharmaceutical ingredients are handled in integrated safety workbenches or flexible isolators reaching OEB level 4 (1-10 µg/m3).
Predefined physicochemical properties of the API can only be achieved by a carefully controlled isolation process. Besides precipitation and crystallization, lyophilization of intermediates and final API is a standard unit operation. LaixingPharma have multiple lyophilizers in different sizes (up to 300 liters) located in clean rooms.
){kind=link}